Lyell Immunopharma, Inc. (LYEL)
NASDAQ · Healthcare
Lyell Immunopharma, Inc. Operating Income 2019–2025
Lyell Immunopharma, Inc. annual/quarterly operating income history and growth rate from 2019 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Lyell Immunopharma, Inc. operating income for the quarter ending March 31, 2026 was -44.3 M, a 22.85% decrease year-over-year.
- Lyell Immunopharma, Inc. operating income for the twelve months ending March 31, 2026 was -186.0 M, a 14.14% decrease year-over-year.
- Lyell Immunopharma, Inc. annual operating income for 2025 was -269.4 M, a 24.91% decrease from 2024.
- Lyell Immunopharma, Inc. annual operating income for 2024 was -358.8 M, a 45.24% increase from 2023.
- Lyell Immunopharma, Inc. annual operating income for 2023 was -247.0 M, a 32.05% increase from 2022.
- Lyell Immunopharma, Inc. annual operating income for 2022 was -187.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Lyell Immunopharma, Inc. Operating Income — FAQ
Lyell Immunopharma, Inc. (LYEL) operating income over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
What is Lyell Immunopharma, Inc.'s operating income?
Lyell Immunopharma, Inc. (LYEL) reported operating income of -$269M for fiscal 2025.
Where can I see LYEL's operating income history?
The chart and table above show Lyell Immunopharma, Inc.'s operating income by year and by quarter, including the growth rate.